Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

BACKGROUND: To improve antitumor effects against metastatic renal cell carcinoma (mRCC), use of molecular target-based drugs in sequential or combination therapy has been advocated. In combination therapy, interferon (IFN)-α amplified the effect of sorafenib in our murine model (J Urol 184:2549, 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Eto, Masatoshi, Kawano, Yoshiaki, Hirao, Yoshihiko, Mita, Koji, Arai, Yoichi, Tsukamoto, Taiji, Hashine, Katsuyoshi, Matsubara, Akio, Fujioka, Tomoaki, Kimura, Go, Shinohara, Nobuo, Tatsugami, Katsunori, Hinotsu, Shiro, Naito, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600287/
https://www.ncbi.nlm.nih.gov/pubmed/26452347
http://dx.doi.org/10.1186/s12885-015-1675-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600287/
https://www.ncbi.nlm.nih.gov/pubmed/26452347
http://dx.doi.org/10.1186/s12885-015-1675-1

Ejemplares similares